Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

$115 million upfront: Eli Lilly will pay Hong Kong-listed Insilico $115m upfront to commercialize some of Insilico's AI-discovered drug candidates globally. The deal validates AI-driven drug discovery, de-risks and accelerates Insilico’s path to market and should be materially positive for Insilico’s valuation while augmenting Lilly’s pipeline with external, AI-originated assets.

Analysis

$115 million upfront: Eli Lilly will pay Hong Kong-listed Insilico $115m upfront to commercialize some of Insilico's AI-discovered drug candidates globally. The deal validates AI-driven drug discovery, de-risks and accelerates Insilico’s path to market and should be materially positive for Insilico’s valuation while augmenting Lilly’s pipeline with external, AI-originated assets.